Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Nivolumab (Opdivo) for recurrent or metastatic squamous cell carcinoma of the head and neck – second line. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2015 Authors' objectives Head and neck cancer is a rare type of cancer. There are over 30 areas in the head and neck where the cancer can develop, for example, the mouth, nose, sinuses and throat. Tobacco smoking and alcohol are known to increase the risk of developing head and neck cancer. Most patients are not diagnosed until the cancer has already spread and is difficult to treat.
Nivolumab is a new drug for the treatment of head and neck cancer which is delivered straight into the bloodstream via a drip. Studies are currently underway to see how well it works and whether it is safe to use in patients with the condition.
If nivolumab is licensed for use in the UK, it could offer a new treatment option for patients with head and neck cancer to help improve survival when current treatments have not worked. Indexing Status Subject indexing assigned by CRD MeSH Antibodies, Monoclonal; Carcinoma, Squamous Cell; Head; Head and Neck Neoplasms; Humans; Neck Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NIHR Horizon Scanning Research&Intelligence Centre, University of Birmingham, Institute of Applied Health Research, Public Health building, Edgbaston, Birmingham B15 2TT
Tel: 0121 414 9077 Email: nihrhsc@contacts.bham.ac.uk AccessionNumber 32016000402 Date abstract record published 04/03/2016 |